Concord Biotech Share Price

₹ 1,163.50

-₹82.10 (-6.59%)
1D
Last updated 02 Nov, 2026, 15:59 IST
NSE: CONCORDBIO
|
Pharmaceuticals

Concord Biotech Share Price Today

As of 3 Nov 2026, Concord Biotech share price is ₹1,163.50. The stock opened at ₹1,207.70, compared to its previous close of ₹1,245.60. During today's trading session, Concord Biotech share price moved in the range of ₹1,156.00 to ₹1,210.00, with an average price of ₹1,183.00 for the day. Looking at its last 52-week, the stock has touched a low of ₹987.00 and a high of ₹1,615.00. On the performance front, Concord Biotech share price has increased by 1.88% over the last six months and is down 19.41% on a year-on-year basis.

Share price over the last 1 day fell from 1192.50 to 1165.00, ranging between 1161.00 and 1204.60.
₹1,156.00
6.59% down today
₹1,210.00
1D LOW
1D HIGH

Concord Biotech Stock Insights

Latest Earning
Op Profit TrendUp by 21.88% QoQ
Latest Earning
Net Profit TrendUp by 20.57% QoQ
Latest Earning
Revenue TrendUp by 18.10% QoQ
Stock Performance
OutperformingBeat Nifty by 8.64 % in last 6 month
Shareholding Pattern
PromoterPromoter increased stake by 0.01%
Shareholding Pattern
DIIDII increased stake by 2.95%
Shareholding Pattern
FIIFII decreased stake by 3.30%
Concord Biotech stock performance
Open₹1,207.70
High₹1,210.00
Low₹1,156.00
Prev. close₹1,245.60
Concord Biotech trading activity
Volume4,08,684
Average traded price₹1,178.38
Last traded time03:59:16 02 Nov
Last traded quantity3
Circuit
L
H
₹930.80
₹1,396.20
52-week
L
H
₹987.00
₹1,615.00
Mkt Cap Cr
13,027.86
P/E
46.64
P/B
6.28
ROA
12.01%
ROE
13.61%
ROCE
18.02%
Quick Ratio
5.46
EV/EBITDA
29.01

Based on fundamentals, this stock's

Performance: 1 out of 5, Very Poor
Performance
Very Poor
Concord Biotech has not beaten FD return of 7%
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Concord Biotech appears overvalued compared to its peers
Earnings: 3 out of 5, Neutral
Earnings
Neutral
Concord Biotech earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,26,661.7438.834.789.61%13.79%18.65%2.3122.27
Divis Laboratories2,57,902.7388.1715.3914.6%15.32%19.56%3.558.97
Torrent Pharmaceuticals1,74,402.4783.099.494.7%11.42%11.37%0.7533.6
Laurus Labs1,26,811.2895.1720.9211.58%22.11%20.91%0.6854.77
Zydus Lifesciences1,24,089.4827.024.588.57%18.59%17.35%0.9116.42
Dr. Reddy's Laboratories1,12,698.5340.842.94.79%7.21%8.58%1.3519.05
Cipla1,11,486.1439.063.156.6%8.18%10.8%2.521.03
Mankind Pharma1,02,796.6045.425.857.82%12.76%14.68%0.7425.01
Aurobindo Pharma96,536.9026.022.556.34%9.25%11.76%1.1512.38
Lupin91,870.1616.554.0914.47%23.76%24.88%1.429.83

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Concord Biotech Company Background

ISIN
INE338H01029
Sector Market Cap
₹ 13,027.86 Cr

Concord Biotech Limited is an India-based research and development-driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. Its business verticals include active pharmaceutical ingredients (API), finished formulations, and contract development and manufacturing services. It manufactures API through fermentation and semi-synthetic processes and finished formulations. The Company’s offerings span both biopharmaceutical APIs and formulations across therapeutic areas like immunosuppressants, oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in antibacterial, antifungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, and Teicoplanin. Its API products under development include Daptomycin, Idarubicin, and Pirarubicin.

Concord Biotech Financial Highlights

  • Revenue: Concord Biotech reported revenue of ₹1,107.25 crore in FY26 vs ₹1,244.54 crore in FY25. It showed a decrease of 11.03% on a yearly basis.
  • Operating Profit: Concord Biotech reported an operating profit of ₹344.65 crore in FY26 vs ₹494.55 crore in FY25. It showed a decrease of 30.31% on a year-on-year basis.
  • Net Profit: Concord Biotech reported a net profit of ₹259.23 crore in FY26 vs ₹371.64 crore in FY25. It showed a decrease of 30.25% on a yearly basis.

Concord Biotech Quarterly Result Highlights

  • Concord Biotech reported revenue of ₹319.24 crore in Sep 2026, compared with ₹270.32 crore in Jun 2026, representing an increase of 18.10% on a quarter-on-quarter (QoQ) basis.
  • Concord Biotech reported an operating profit of ₹95.48 crore in Sep 2026, compared with ₹78.34 crore in Jun 2026, representing an increase of 21.88% on a quarter-on-quarter (QoQ) basis.
  • Concord Biotech reported a profit of ₹69.57 crore in Sep 2026, compared with ₹57.70 crore in Jun 2026, reflecting an increase of 20.57% on a QoQ basis.
  • The earnings per share (EPS) of Concord Biotech stood at ₹24.78 during Sep 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
44.09%
FII
7.28%
Other DII
5.11%
Retail and other
37.68%
Mutual funds
5.84%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 20257.58%
Mar 20267.80%
Jun 20267.52%
Sep 20267.28%

Concord Biotech Investment Returns

1 day
-6.59%
1 week
-11.26%
1 month
-15.33%
1 year
-19.41%
3 years
+2.91%
5 years
+23.41%

Concord Biotech Share Price History

Concord Biotech share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
02 Nov 26
₹1,207.70 / ₹1,163.50
-6.59%
30 Oct 26
₹1,224.30 / ₹1,245.60
+1.22%
29 Oct 26
₹1,264.70 / ₹1,230.60
-2.99%
28 Oct 26
₹1,319.90 / ₹1,268.50
-7.77%
Show more

Concord Biotech Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,054.89₹1,200.09₹1,016.94₹853.17
Other Income₹52.36₹44.45₹33.78₹35.31
Total Revenue₹1,107.25₹1,244.53₹1,050.72₹888.48
Total Expenses₹762.23₹748.66₹641.53₹568.42
Profit Before Tax₹344.65₹494.55₹412.57₹322.01
Tax₹85.42₹122.91₹104.46₹81.93
Profit After Tax₹259.23₹371.64₹308.10₹240.09
EPS - Basic₹24.78₹35.52₹29.45₹22.95
EPS - Diluted₹24.78₹35.52₹29.45₹22.95

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹344.65₹494.55₹412.57₹322.01
Income before WC changes₹381.21₹524.69₹450.00₹368.56
Change in Assets-₹10.48-₹216.44-₹73.97-₹79.46
Change in Liabilities-₹3.44₹45.68-₹7.21₹27.17
Change in WC-₹13.92-₹170.76-₹81.18-₹52.29
Cash flow from Operations₹266.88₹244.52₹265.47₹246.00
Cash flow from Investing-₹142.72-₹159.99-₹154.61-₹157.95
Cash flow from Financing-₹112.88-₹98.77-₹99.21-₹85.22
Total Cash Flow₹11.28-₹14.24₹11.64₹2.83
Cash (Start of the year)₹0.90₹15.14₹3.50₹0.67
Cash (End of the year)₹12.19₹0.90₹15.14₹3.50

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹984.62₹899.01₹804.48₹786.28
Current Assets₹1,250.11₹1,135.24₹896.23₹727.70
Total Assets₹2,234.73₹2,034.25₹1,700.71₹1,513.98
Current Liabilities₹169.08₹184.06₹142.16₹191.84
Net Current Asset₹1,081.03₹951.18₹754.08₹535.86
Non-Current Liabilities₹50.51₹37.47₹31.91₹32.14
Equity Capital₹2,015.14₹1,812.72₹1,526.65₹1,290.00
Total Equity & Liabilities₹2,234.73₹2,034.25₹1,700.71₹1,513.98

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,055.07₹1,200.09₹1,016.94₹853.17
Other Income₹52.73₹44.45₹33.78₹35.31
Total Revenue₹1,107.80₹1,244.53₹1,050.72₹888.48
Total Expenses₹753.09₹748.66₹641.53₹568.42
Profit Before Tax₹351.43₹495.88₹409.19₹320.05
Tax₹88.17₹122.91₹104.46₹81.93
Profit After Tax₹263.27₹372.96₹304.73₹238.13
EPS - Basic₹25.17₹35.65₹29.13₹22.76
EPS - Diluted₹25.17₹35.65₹29.13₹22.76

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹351.43₹495.88₹409.19₹320.05
Income before WC changes₹390.37₹524.69₹450.00₹368.56
Change in Assets-₹24.61-₹216.44-₹73.97-₹79.46
Change in Liabilities-₹4.51₹45.68-₹7.21₹27.17
Change in WC-₹29.12-₹170.76-₹81.18-₹52.29
Cash flow from Operations₹263.78₹244.52₹265.47₹246.00
Cash flow from Investing-₹142.28-₹159.99-₹154.61-₹157.95
Cash flow from Financing-₹114.51-₹98.77-₹99.21-₹85.22
Total Cash Flow₹6.98-₹14.24₹11.64₹2.83
Cash (Start of the year)₹0.90₹15.14₹3.50₹0.67
Cash (End of the year)₹7.89₹0.90₹15.14₹3.50

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹991.32₹898.94₹803.08₹786.95
Current Assets₹1,245.22₹1,135.24₹896.23₹727.70
Total Assets₹2,236.54₹2,034.18₹1,699.32₹1,514.65
Current Liabilities₹167.24₹184.06₹142.16₹190.53
Net Current Asset₹1,077.97₹951.18₹754.08₹537.17
Non-Current Liabilities₹49.54₹37.47₹31.91₹32.14
Equity Capital₹2,019.75₹1,812.65₹1,525.25₹1,291.98
Total Equity & Liabilities₹2,236.54₹2,034.18₹1,699.32₹1,514.65
* All values are in INR Crore
Concord Biotech market depth
Bid quantityBid priceAsk priceAsk quantity
281163.500
0000
0000
0000
0000
Total bid quantity28
Total ask quantity0
Concord Biotech technical summary
Bearish indicators2
Neutral indicators4
Bullish indicators2
OverallNeutral
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
39.66
Neutral
ATR (14)
59.72
Neutral
STOCH(9,6)
18.25
Bullish
STOCH RSI (14)
48.11
Neutral
ADX(9)
31.61
Bearish
UO(9)
42.01
Neutral
ROC(12)
-9.06
Bearish
WillR(14)
-81.92
Bullish
Period
Simple value
Exponential vaue
5D
1286.24
1266.66
10D
1282.6
1287.22
20D
1321.81
1322.41
50D
1420.1
1367.73
100D
1381.14
1349.1
Volume trend — traded volume by day
2 Nov4L
30 Oct1L
29 Oct1L
28 Oct3L
27 Oct1L
Average2L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Concord Biotech
Pharmaceuticals
Add Stock
Add Another

Concord Biotech Returns Calculator

Ex-date: 24 Jul 2026

Concord Biotech Latest News

1 month ago
Concord Biotech shares fall 5% after bonus issuance approval; board nods authorised capital increase to ₹22 crore
1 month ago
Welspun Corp, Concord, HEG among buzzing stocks as SENSEX soars 600 pts; NIFTY trades above 23,400
1 month ago
Concord Biotech shares surge 5% as board to meet on September 23 to consider bonus issue; check details
4 months ago
NIFTY50 above 23,375, SENSEX up 518 pts in noon deals; RIL, Clean Max Enviro, CMR Green Tech among buzzing stocks
4 months ago
Concord Biotech shares jump 6% on receiving US FDA approval for its latest arthritis drug
5 months ago
IndiGo, NHPC, Concord Biotech among buzzing stocks as SENSEX falls over 600 pts, NIFTY below 23,300
5 months ago
Concord Biotech shares jump over 8% after US FDA approves latest Mycophenolate Mofetil drug
Showing news item 1 of 7

Top Gainers

ITI Share Price
₹259.14
+43.19 (+20%)
ENGINERSIN Share Price
₹289.65
+37.8 (+15.01%)
AFFLE Share Price
₹1506.50
+164.7 (+12.27%)
PRAJIND Share Price
₹271.13
+29.43 (+12.18%)
DIXON Share Price
₹12319.00
+1319 (+11.99%)
See more

Top Losers

INDIGOPNTS Share Price
₹870.00
-127.3 (-12.76%)
CLEAN Share Price
₹662.60
-53 (-7.41%)
ZEEL Share Price
₹61.58
-4.82 (-7.26%)
SYRMA Share Price
₹1512.00
-113.3 (-6.97%)
POLICYBZR Share Price
₹931.00
-69.1 (-6.91%)
See more

Concord Biotech Share Price FAQs

Please be aware that Concord Biotech stock prices are subject to continuous fluctuations due to various factors.